EBI2 Expression and Function: Robust in Memory Lymphocytes and Increased by Natalizumab in Multiple Sclerosis. by Clottu, A.S. et al.
ArticleEBI2 Expression and Function: Robust in Memory
Lymphocytes and Increased by Natalizumab in
Multiple SclerosisGraphical AbstractHighlightsd EBI2 expression is maximal on human CD4+ T cells and
CD19+ B cells
d EBI2 is functional in human T and B cells
d Natalizumab alters EBI2 expression and function in memory
CD4+ T cellsClottu et al., 2017, Cell Reports 18, 213–224
January 3, 2017 ª 2017 The Author(s).
http://dx.doi.org/10.1016/j.celrep.2016.12.006Authors
Aure´lie S. Clottu, Amandine Mathias,
Andreas W. Sailer, Myriam Schluep,
Jo¨rg D. Seebach, Renaud Du Pasquier,
Caroline Pot
Correspondence
caroline.pot-kreis@chuv.ch
In Brief
Clottu et al. investigated the expression
and function of the oxysterol receptor
EBI2 in human primary lymphocytes.
They show that EBI2 regulates human
lymphocyte migration in vitro and that its
expression and migratory response are
increased in memory CD4+ T cells from
multiple sclerosis patients treated with
natalizumab.
Cell Reports
ArticleEBI2 Expression and Function: Robust
in Memory Lymphocytes and Increased
by Natalizumab in Multiple Sclerosis
Aure´lie S. Clottu,1,2,3 Amandine Mathias,1 Andreas W. Sailer,4 Myriam Schluep,5 Jo¨rg D. Seebach,3
Renaud Du Pasquier,1,5 and Caroline Pot1,2,5,6,*
1Laboratories of Neuroimmunology, Neuroscience Research Center, Department of Clinical Neurosciences, Lausanne University Hospital,
Chemin des Boveresses 155, 1066 Epalinges, Switzerland
2Department of Pathology and Immunology, Geneva University Medical Center, Rue Michel-Servet 1, 1211 Geneva 4, Switzerland
3Division of Immunology and Allergology, Department of Medical Specialties, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4,
1211 Geneva 14, Switzerland
4Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Forum 1, 4002 Basel, Switzerland
5Division of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital, Rue du Bugnon 46, 1011 Lausanne, Switzerland
6Lead Contact
*Correspondence: caroline.pot-kreis@chuv.ch
http://dx.doi.org/10.1016/j.celrep.2016.12.006SUMMARY
The interaction between oxysterols and the G pro-
tein-coupled receptor Epstein-Barr virus-induced
gene 2 (EBI2) fine-tunes immune cell migration, a
mechanism efficiently targeted by several disease-
modifying treatments developed to treat multiple
sclerosis (MS), such as natalizumab. We previously
showed that memory CD4+ T lymphocytes migrate
specifically in response to 7a,25-dihydroxycholes-
terol (7a,25-OHC) via EBI2 in the MS murine model
experimental autoimmune encephalomyelitis. How-
ever, the EBI2 expression profile in human lympho-
cytes in both healthy and MS donors is unknown.
Here, we characterize EBI2 biology in human lym-
phocytes. We observed that EBI2 is functionally ex-
pressed on memory CD4+ T cells and is enhanced
under natalizumab treatment. These data suggest a
significant role for EBI2 in human CD4+ T cell migra-
tion, notably in patientswithMS. Better knowledge of
EBI2 involvement in autoimmunity may therefore
lead to an improved understanding of the physiopa-
thology of MS.
INTRODUCTION
Multiple sclerosis (MS) is a frequent chronic inflammatory dis-
ease of the CNS leading to neurologic disability and lifelong
morbidity in young adults (Compston and Coles, 2002). Despite
advances in MS research, its pathophysiology is still far from be-
ing well understood, so it remains an incurable disease. In addi-
tion, many patients still do not respond appropriately to available
drugs or experience heavy side effects. Inflammation in MS in-
volves circulating auto-reactive T cells, which escape immune
regulation and enter the brain, resulting in inflammatory infiltratesCe
This is an open access article under the CC BY-Nand demyelination throughout the CNS (Compston and Coles,
2002). Thus, immune cell migration is a key point in the disease
process (Engelhardt and Ransohoff, 2012). Subsets of oxidized
cholesterol metabolites, oxysterols, were reported to play a
role in inflammation and immune cell chemotactism (Bauman
et al., 2009; Yi et al., 2012). More precisely, the oxysterol
7a,25-dihydroxycholesterol (7a,25-OHC), synthesized through
the enzymes cholesterol 25-hydroxylase and 25-hydroxycholes-
terol 7-alpha-hydroxylase, was characterized as having peculiar
chemotactic properties by being the strongest ligand activating
the Epstein-Barr virus-induced gene 2 (EBI2) receptor (Hanne-
douche et al., 2011; Liu et al., 2011). The expression of this re-
ceptor is well characterized on murine immune cells and found
to be maximal on mature B cells and CD4+ T cells, including T
follicular helper (Tfh) cells, but is also described on dendritic cells
(DC) and plasmacytoid DCs (pDCs) (Chiang et al., 2013; Gatto
et al., 2013; Li et al., 2016; Pereira et al., 2009; Suan et al.,
2015). In vivo, EBI2 activation was reported to direct B and Tfh
cell positioning in follicles and osteoclasts migration toward
bone surface (Gatto et al., 2009; Kelly et al., 2011; Li et al.,
2016; Nevius et al., 2015; Pereira et al., 2009; Suan et al.,
2015; Yi et al., 2012). We showed that EBI2 promoted memory
CD44+CD4+ T cell, particularly interleukin (IL)-17-secreting
T cell, and migration during experimental autoimmune encepha-
lomyelitis (EAE) (Chalmin et al., 2015). In human, EBI2 is further
expressed and promotes the in vitro migration of astrocytes
and macrophages (Eibinger et al., 2013; Preuss et al., 2014; Rut-
kowska et al., 2015). However, the expression and the function of
EBI2 in human lymphocytes are scarcely studied, while EBI2’s
potential role in MS and the impact of disease-modifying treat-
ments (DMTs) on this receptor biology have not been examined.
In this study, we aimed to characterize the expression and func-
tion of EBI2 in human peripheral blood lymphocytes by using
flow cytometry and an in vitro migration assay. We tested lym-
phocytes obtained from healthy donors (HDs) and relapsing-
remitting multiple sclerosis (RRMS) patients who were either
untreated or receiving a DMT, in particular natalizumab, all Reports 18, 213–224, January 3, 2017 ª 2017 The Author(s). 213
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Memory CD4  T cell subsets
        CD4  T cell subsets
CD19 CD4 CD8 NKT  NK
0
2 0
4 0
6 0
NS
***
NS
A B
CD19 CD4 CD8 CD19 CD4 TCM TEM CD8
1
10
100
1000
*
*
*
Memory subsetsNaive subsets
E
B
I2
 M
F
IR
E
B
I2
M
F
IR
C
D
27
EBI2
EBI2
C
D
45
R
A
C
D
27
Isotype
C
D
45
R
A
Isotype
E
B
I2
 (M
FI
R
)
E
B
I2
 (M
FI
R
)
Gated on CD19  B cells       +
Th17 Th1 Th2
C
E
C
D
45
R
A
Gated on CD4  T cells       +
Gated on naive CD4  T cells       + Gated on memory CD4  T cells       +
+
+
E
B
I2
 (M
FI
R
)
Gated on naive CD19  B cells+ Gated on memory CD19  B cells+
D
Naive Memory Th1 Th2  Th17
1
1 0
1 00
E
B
I2
 (
M
FI
R
)
Figure 1. EBI2 Expression in Human Lymphocytes from HDs
Cryopreserved human peripheral blood mononuclear cells (PBMCs) were analyzed by flow cytometry.
(A) EBI2 expression shown asmean fluorescence intensity ratios (MFIRs) in total CD19+ B, CD4+ T, CD8+ T, NKT (CD3+CD56+), and NK (CD3CD56+) cells, gated
after dead cells and doublet exclusion.
(B) EBI2 MFIRs in naive (CD19+CD27) and memory (CD19+CD27+) subsets of B cells and in naive (CD45RA+) and memory (CD45RA) CD4+ and CD8+ T cells,
with CD4+ T cell effector memory (TEM, CCR7) and central memory (TCM, CCR7+) subtypes.
(C) Fluorescence histograms showing EBI2 (dark gray) and isotype (light gray) in naive versus memory subsets of CD4+ T cells (upper panels) and CD19+ B cells
(lower panels).
(D) Comparison between isotype (left) or EBI2 (right) stainings in CD4+ T cells (upper) or B cells (lower). Numbers in each quadrant indicate the percentage of cells.
(legend continued on next page)
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humanized monoclonal immunoglobulin G4 (IgG4) (Bo¨rnsen
et al., 2012) antibody blocking the a4-integrin subunit and thus
interfering with leukocytes migration to the CNS (Engelhardt
and Kappos, 2008).
RESULTS
EBI2 Is Highly Expressed on Human Memory
Lymphocytes
To characterize the role of EBI2 in human lymphocytes, we first
analyzed its expression by flow cytometry on different subsets of
human peripheral blood mononuclear cells (PBMCs) from HDs
using a specific anti-EBI2 antibody (clone 57C9B5C9) (Rut-
kowska et al., 2015) or the corresponding isotype. EBI2 was de-
tected at the highest level in CD19+ B cells and CD4+ T cells with
an average of mean fluorescence intensity ratios (MFIRs) 20
times higher compared to CD8+ T, natural killer T (NKT), and
NK cells that showed low EBI2 expression (Figures 1A and
S1A). Using the EAE model, we previously reported that
CD4+CD44+ memory lymphocytes depicted higher EBI2 expres-
sion and migration toward 7a,25-OHC compared to their naive
correlates (Chalmin et al., 2015). Therefore, we here asked
whether memory versus naive lymphocyte subsets would differ-
entially express EBI2 in the human setting as well. The highest
EBI2 expression was detected in memory subsets of lympho-
cytes, with memory T (CD45RACD4+) and B (CD27+CD19+)
cells expressing significantly more EBI2 compared to their naive
counterparts (Figures 1B and S1A). In the B cell subset, CD27 is
also co-expressed with CD19+ on plasmablasts that do not ex-
press the CD20marker. However, a contribution of plasmablasts
to EBI2 expression is unlikely, because we did not detect a
significant amount of CD19+CD20 B cells in our samples
(data not shown). Memory CD4+ T cells can be further divided
into two memory pools, the T central memory (TCM) and T
effector memory (TEM) subsets, that have distinct homing po-
tentials and are characterized by a different expression of C-C
chemokine receptor 7 (CCR7) (Sallusto et al., 1999). Some sub-
sets of integrins and chemokine or sphingosine receptors impli-
cated in leukocyte trafficking have been shown to have distinct
actions on these two subsets (Mehling et al., 2008; Sallusto
et al., 1999). We therefore wondered whether EBI2 expression
could diverge in the latter populations, but we detected similar
EBI2 expression levels between them (Figures 1B and S1A).
Memory CD45RACD8+ T cells also depicted higher EBI2
expression compared to naive subsets, although at very low
levels compared to B and CD4+ T cells (Figure 1B).
We further questioned whether the entire versus parts of the
memory cell population expressed EBI2. Compared to the iso-
type, the EBI2 staining revealed a predominant fluorescence
shift in thememory subsets of CD4+ T andCD19+ B cells (Figures
1C and S1A) associated to a deviation of the entire memory but
not of the naive populations, without the apparition of a distinct(E) Left: fluorescence histograms showing EBI2 (dark gray) and isotype (light gra
Right: EBI2 MFIRs in naive and memory CD4+ T cells, and Th1, Th2, and Th17 s
Statistics using two-way ANOVA with a Tukey’s post hoc analysis or unpaired
represent median. See also Figure S1.subpopulation neither in the CD19+ B nor in the CD4+ T cell sub-
sets (Figures 1D and S1A).
We next examined whether EBI2 would be differentially ex-
pressed in differentiated subsets of CD4+ T helper cells, because
we had previously shown using the murine EAE model that Th17
cells migrated maximally toward 7a,25-OHC and probably ex-
pressed EBI2 at a higher level compared to other CD4+ T cell sub-
sets. We therefore looked at ex vivo EBI2 expression on Th1, Th2,
and Th17 memory subtypes defined using chemokine receptor
surface markers (Th1, CXCR3+CCR4; Th2, CXCR3CCR4+;
and Th17, CXCR3CCR6+). Although Th17 cells showed a slightly
increased shift in EBI2 expression compared to Th1 or Th2 sub-
sets, no statistical difference in MFIRs was observed between
them (Figures 1E and S1B).
Migration toward 7a,25-OHC Is Maximal in Memory
CD4+ T Cells and EBI2 Dependent
To investigate whether EBI2 was functional and could promote
lymphocyte trafficking, we tested the migration response of hu-
man whole PBMCs toward different concentrations of 7a,25-
OHC in a transwell assay as previously described formurine lym-
phocytes (Chalmin et al., 2015). In our model, migration was
highest at 300 nM, particularly in the memory CD4+ T cells,
with a concentration effect between 300 nM (mean 13.4 ± SD
7.5) and 3,000 nM (8.4 ± 5.5). Consistent with EBI2 expression
profiles, the migration was maximal in lymphocyte memory sub-
sets (Figure 2A, lower panels), with a response five times
higher at the concentration of 300 nM in memory CD4+ T cells
(13.4 ± 7.5) compared to naive (2.4 ± 1) (Figure 2A, upper panels).
Memory B cells showed half-lower migration compared to mem-
ory CD4+ T cells, while CD8+ T cells migrated at the lowest level.
Furthermore, we confirmed that the migration was EBI2 depen-
dent in our model. Because such directed migration involves a
gradient of EBI2 ligand, here 7a,25-OHC, we disrupted the
gradient by adding the same amount of 7a,25-OHC in both the
upper and the lower chambers. Abolishment of the gradient
significantly decreasedmemoryCD4+T cellmigration (Figure 2B,
left panel). We further inhibited the EBI2 receptor using a chem-
ical compound, NIBR189, previously characterized to selectively
inhibit this receptor (Gessier et al., 2014). NIBR189 dramatically
diminished the migration of memory CD4+ T cells in a concentra-
tion-dependent manner when added with the PBMCs in the
transwell migration assay; the most efficient concentration in
our model was determined to be 25 nM (Figure 2B, middle
panel). To compare EBI2-dependent migration to a known
lymphocyte chemoattractant, we used CXCL12 (SDF-1) (Liu
and Dorovini-Zis, 2009) in our assay and found that the migration
of memory CD4+ T cells toward this agent was three times higher
than the response obtained with 7a,25-OHC. In contrast, migra-
tion in response to CXCL12 was not affected by NIBR189 addi-
tion (Figure 2B, right panel). NIBR189 did not change cell viability
(Figure 2C) or induced toxicity in lymphocytes (Figure 2D).y) in Th1 (CXCR3+CCR4), Th2 (CXCR3CCR4+), and Th17 (CXCR3CCR6+).
ubsets (n = 5).
Student’s t test, with a p value % 0.05 considered significant (*). Error bars
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EBI2 Is Functionally Expressed in MS Patients with a
Distinct EBI2 Expression to Migration Correlation
Pattern
After the characterization of EBI2 in HDs, we proposed to assess
its role in a disease setting, i.e., in RRMSpatients (characteristics
detailed in Table 1), because we had previously shown that EBI2
affects memory CD4+ T cell migration to the CNS during EAE
(Chalmin et al., 2015). We first tested untreated RRMS patients
experiencing a relapse at the time of blood drawing. The re-
lapses were characterized by non-invalidating symptoms, and
the patients were not treated with corticosteroids. The detected
EBI2 expression levels in CD19+ B cell, CD4+ T cell, and CD8+
T cell subsets from these RRMS patients was similar to HDs,
but the data repartition showed a higher variability, especially
in memory CD4+ T cells (HD: 72.4 (±45) versus RRMS: 86.1
(±108)) (Figure 3A). The migration response to 7a,25-OHC was
also maximal in all memory subsets, and reached the same
levels as in HDs, with average migration ratios in memory
CD4+ T cells of 12 (±7) and 11 (±7) in HDs and RRMS patients,
respectively, and a concentration effect from 7a,25-OHC 300
to 3,000 nM both in HDs (25% decrease of the median of
migration ratios) and in RRMS patients (38% decrease of me-
dian) (Figure 3B). We further evaluated the correlation between
EBI2 expression and migration toward 7a,25-OHC. Although
we observed no correlation in all subsets of lymphocytes from
HDs (Figure 3C, upper panels), in RRMS patients, we detected
a positive correlation reaching statistical significance in memory
CD8+ T cells (p = 0.0143) and a positive trend in memory CD4+
T cells (p = 0.0885) (Figure 3C, lower panels).
Natalizumab Treatment Increases EBI2 Expression and
Promotes Migration toward 7a,25-OHC in Memory CD4+
T Cells
Natalizumab (NTZ) is a humanized monoclonal IgG4 antibody
blocking the a4-integrin subunit (Bo¨rnsen et al., 2012; Engelhardt
and Kappos, 2008). The latter associates in a heterodimer with
b1 to form an adhesion molecule also called very late antigen-
4 (VLA-4), which is required for immune cell migration to the brain
by interacting with its main ligands: vascular-cell adhesion mole-
cule 1 (VCAM-1) and fibronectin. VCAM-1 is expressed on CNS
vessel endothelial cells and is upregulated during neuroinflam-
mation (Engelhardt and Kappos, 2008). Other integrin ligands,
such as intercellular adhesion molecule (ICAM)-1 and ICAM-2,Figure 2. Human Memory Lymphocytes from HDs Migrate toward 7a,2
HDPBMCmigrationwas assessed by transwell assay and quantified by flow cytom
cells migrating to a given condition divided by the number of cells migrating to m
(A) Migration in response to 7a,25-OHC (0, 300, and 3,000 nM) of CD19+ B cells
(lower panels) subsets (n = 16).
(B) Left: migration toward 7a,25-OHC (0 or 300 nM) of memory CD4+ T cells withou
CD4+ T cells toward 7a,25-OHC (0 or 300 nM) with or without different concentratio
(0 or 100 ng/mL) with or without NIBR189 (n = 2) (25 nM).
(C) Human PBMCs were kept in culture medium for 3 hr at 37C either with only
analyzed by flow cytometry. Numbers in quadrants indicate the percentage of c
(D) Human PBMCs were processed and incubated as in (C) with the following c
3,000 nM), 7a,25-OHC 300 nM, 7a,25-OHC 3,000 nM, or NIBR189 25 nM, with
measured by spectrophotometry.
Statistics using two-way ANOVA with a Tukey’s post hoc analysis, with a p value
in (B).which bind aLb2 (CD11a/CD18), also called leukocyte function-
associated antigen-1 (LFA-1) on T cells, are upregulated upon
CNS inflammation (Engelhardt and Ransohoff, 2012). The major
effect of NTZ is to strongly inhibit themigration of immune cells to
the brain, and is used in clinics with a significant beneficial effect
to prevent relapses and possibly progression of disability in pa-
tients with RRMS (Polman et al., 2006).
Because NTZ has been shown to alter cell surface molecules
expression, such as LFA-1, we hypothesized that EBI2 expres-
sion and/or function may be changed upon NTZ treatment as
well (Jilek et al., 2014). Therefore, we assessed EBI2 expression
by flow cytometry and performed transwell assay as described
earlier to analyze samples from RRMS patients before (T0) and
after 9–12 months (T9–T12) of NTZ treatment (patient character-
istics detailed on Table 1). We first confirmed that in this patient
population, EBI2 expression was predominant in the memory
subsets of CD4+ and CD8+ T cells and of B cells both at T0
and at T9–T12. However, EBI2 expression increased specifically
in all memory CD4+ T cell populations (total, central, and effector
memory), with MFIRs increasing as much as three times under
NTZ treatment. No consistent MFIR change was detected in
the CD8+ T cell or the CD19+ B cell subsets at T9–T12 compared
to T0 (Figure 4A). Because NTZ treatment is prescribed in pa-
tients experiencing aggressive disease courses, we wanted to
determine whether the increase in EBI2 expression could be
related to disease duration or disease severity, rather than to
the treatment. EBI2 expression showed a correlation with neither
disease evolution nor disease severity, expressed by the
expanded disability status scale (EDSS) (Figure S2A). We further
checked whether changes in EBI2 expression could be induced
by another DMT.We thus analyzed samples frompatients before
(T0) and after 9–12 months (T9–T12) of dimethyl fumarate (DMF)
treatment. We did not observe any significant changes in EBI2
expression under this drug (Figure S2B and Table S1).
We then assessed whether NTZ could enhance EBI2 function.
When looking at the migration of paired samples at two time
points of NTZ treatment, we noticed again a predominant
response in all memory subsets, and consistent with EBI2
expression, an increase of migration at T9–T12 was seen only
in memory CD4+ T cells (Figure 4B). We further examined
whether NIBR189 was sufficient to block EBI2-induced migra-
tion of NTZ-treated patient memory CD4+ T cells and thus per-
formed in vitro migration assay with NTZ patient PBMCs at5-OHC in an EBI2-Dependent Way In Vitro
etry using flow count beads. Themigration ratio corresponds to the number of
edium only (concentration 0 nM).
, CD4+ T cells, and CD8+ T cells in naive (upper panels) compared to memory
t or with addition of 7a,25-OHC to the cells (n = 4). Middle: migration of memory
ns of NIBR189 (n = 2). Right: migration ofmemory CD4+ T cells toward CXCL12
culture medium or with additional NIBR189 (25 nM), stained for viability, and
ells. FS, forward scatter; SS, side scatter.
onditions: water, DMSO (amount equivalent to a concentration of 7a,25-OHC
lysis buffer as positive control. The lactate dehydrogenase (LDH) release was
% 0.05 considered significant (*). Error bars represent median in (A) and SEM
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Table 1. Patient Characteristics
Gender
Mean Age
(±SEM) n
Mean EDSS
at T0 (±SEM)
Mean EDSS during
T9–T12 (±SEM)
Disease Mean Duration
(Years) at Blood Draw (±SEM) Previous DMT
Healthy
donors
female 37.42 (3.40) 12 – – – –
male 34.50 (3.75) 4 – – – –
RRMS
patients
female 35.22 (2.06) 11 2.14 (0.19) – 2.57 (1.32) 11 no treatment
male 34.60 (3.61) 4 1.88 (0.24) – 1.85 (1.14) 3 no treatment
1 natalizumab (stopped 5 months
before sampling)
NTZ
patients
female 33.72 (3.32) 10 2.75 (0.45) 2.45 (0.43) 6.40 (1.94) 6 interferon-beta
2 glatiramer acetate
1 fingolimod (stopped 2 months
before sampling)
1 untreated
male 39.00 (0.00) 1 3.00 (0.00) 3.00 (0.00) 7.00 (0.00) no treatment (interferon-beta stopped
12 months before sampling)
Clinical features from patients included in the study. Age and disease duration are in years. RRMS, relapsing-remitting multiple sclerosis; NTZ,
natalizumab treated; DMT, disease-modifying treatment; T, time (months); EDSS, expanded disability status scale.T0 and at T9–T12. At both time points, EBI2 inhibition was
equally efficient in memory CD4+ T cells (from a mean
of 11.8 (±4) to 1.8 (±0.5) at T0 and 18.2 (±8) to 1.6 (±0.7) at
T9–T12) despite the increase in migration toward 7a,25-OHC
at T9–T12 (Figure 4C).
We next asked whether EBI2 expression was correlated to
migration toward 7a,25-OHC. As seen in RRMS samples, there
was a positive correlation at NTZ T0 and at NTZ T9–T12 in
CD4+ T cells (Figure 4D). However, no difference in correlation
was observed between the two time points.
We then determined whether NTZ could increase EBI2
expression when added directly on memory CD4+ T cells
in vitro. PBMCs were cultured in vitro in the presence or not of
physiologic concentrations of NTZ (100 mg/mL, corresponding
to themaximum serum concentration observed in humans) (Kivi-
sa¨kk et al., 2009). The sole addition of NTZ on memory CD4+
T cells in vitro was not able to upregulate EBI2 (Figure S3A).
However, 7a,25-OHC exposition decreased EBI2 expression
levels when added in parallel, thus confirming that modulation
of human EBI2 at the protein level was feasible in vitro
(Figure S3B).
EBI2 and CD11a Expressions Are Negatively Correlated
in Memory CD4+ T Cells during Natalizumab Treatment
To compare the evolution of EBI2 expression to another marker
known to be affected by NTZ, we decided to assess the expres-
sion of the a subunit of LFA-1, CD11a, which was shown to
decrease in T cells upon NTZ treatment (Jilek et al., 2014). In
our patients, CD11a fluorescence was predominant in memory
subsets of CD4+ T cells, and its expression was significantly
diminished at T9–T12 compared to T0 in all CD4+ and CD8+
T cell subsets (Figure 5A) but not in B cells. We next wondered
whether EBI2 and CD11a were co-expressed on memory
CD4+ T cells. Most EBI2-positive cells co-expressed CD11a
(Figure 5B). Under NTZ treatment, the percentage of cells co-ex-
pressing EBI2 with CD11a was not altered; however, the per-
centage of memory CD4+ T cells that were EBI2 single positive218 Cell Reports 18, 213–224, January 3, 2017increased significantly while the percentage of cells single posi-
tive for CD11a decreased significantly (Figure 5B, plots and
graphic). Those results suggest a possible interaction between
those two surface receptors.
DISCUSSION
Oxysterols and EBI2 have received growing attention in the field
of immunology, with works highlighting an important role for
EBI2 in immune cell migration. However, these studies are
mainly limited to animal models (Chalmin et al., 2015; Hanne-
douche et al., 2011; Kelly et al., 2011; Liu et al., 2011; Pereira
et al., 2009; Suan et al., 2015), while in human and particularly
in a disease setting, such as MS, the relevance of EBI2 expres-
sion and function remains a critical question to potentially trans-
late research findings from the bench side to the patient.
We here report that EBI2 is functional and differentially ex-
pressed at the surface of human lymphocytes, with a strong pre-
dominance for CD4+ T and B cell memory subsets. These obser-
vations obtained at the protein level are in line with previous
mRNA data (Hannedouche et al., 2011) showing predominant
EBI2 expression in human memory subsets of B cells and
CD4+ and CD8+ T cells, and they corroborate murine data
showing a higher EBI2 expression in mature B cells compared
to naive correlates (Pereira et al., 2009). Curiously, despite
similar EBI2 expression levels between memory CD4+ T cells
and B cells, CD4+ T cells migrate twice as much as their B cell
counterparts. Technically, this could be secondary to differences
between B and CD4+ T cells about the optimal oxysterol concen-
trations for migration in our assay or to a higher sensitivity of B
cells to the thawing process. However, previous murine data
show a similar migration between B220+ B cells and CD4+
T cells (Liu et al., 2011). Therefore, possible differences between
human B and CD4+ T cell migration patterns cannot be dis-
missed, and they could be secondary to differences in EBI2
signaling or to distinct interactions with other adhesion or activa-
tion molecules. No positive correlation between the migration
AB
C
Figure 3. EBI2 Expression and Migration Rate in Lymphocytes from Untreated RRMS Patients
(A) EBI2 MFIRs in memory B and CD4+ T cells in HDs (n = 16) and RRMS patients (n = 15).
(B) Migration rates toward 7a,25-OHC (0, 300, and 3,000 nM) in memory subsets of CD19+ B cells, CD4+ T cells, and CD8+ T cells from HDs (n = 16) and RRMS
patients (n = 14).
(C) Correlation of EBI2 expression (MFIR) andmigration toward 7a,25-OHC300 nM inmemoryCD19+ B cells, CD4+ cells andCD8+ T cells fromHDs (n = 16, upper
panels) or untreated RRMS patients (n = 14, lower panels).
Statistical analysis used two-way ANOVAwith a Tukey’s post hoc analysis or unpaired t test, linear regression, and Pearson correlation test, with a p value% 0.05
considered significant (*). Error bars represent median.rate toward 7a,25-OHC and EBI2 expression was observed in
different subsets of lymphocytes obtained from HDs. On the
contrary, a positive correlation between EBI2 expression and
migration toward 7a,25-OHC was observed in RRMS patients
(both untreated or under DMTs). This is particularly relevant for
CD4+ and CD8+ memory T cells but not for CD19+ B cells. Those
correlation differences between HDs and RRMS patients couldindicate that EBI2 signaling or interactions with other adhesion
molecules differ during autoimmunity.
In addition, the similar levels of EBI2 expression in untreated
RRMS patients might not exclude changes in EBI2 expression
and/or function in more severe disease states or at precise mo-
ments during the disease evolution. Because it was described
that upon certain stimuli (i.e., lipopolysaccharides [LPS]Cell Reports 18, 213–224, January 3, 2017 219
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Figure 4. Memory CD4+ T Cells from NTZ-
Treated Patients Show Increased EBI2
Expression and Migration Response to
7a,25-OHC
Cryopreserved PBMCs from RRMS patients
before (T0) or after 9–12 months of NTZ treatment
(T9–T12) were analyzed by flow cytometry for EBI2
expression, and migration was assessed by
transwell assay.
(A) EBI2 expression shown as MFIRs in CD4+
T cell, CD8+ T cell, and CD19+ B cell naive and
memory subsets (n = 11), including TCM and TEM
(n = 10).
(B) Migration in response to 7a,25-OHC (0, 300,
and 3,000 nM) in naive (upper panels) versus
memory (lower panels) subsets of CD4+ and CD8+
T cells, as well as CD19+ B cells.
(C) Migration in response to 7a,25-OHC (0 and
300 nM) of memory CD4+ T cells from RRMS pa-
tients before and after NTZ treatment onset
without or with EBI2 inhibition by NIBR189 (n = 11).
(D) Correlation of EBI2 expression (MFIR) with
migration toward 7a,25-OHC 300 nM in NTZ T0
(left panel) and NTZ T9–T12 (right panel) (n = 11).
Statistical analysis using two-way ANOVA with a
Tukey’s post hoc analysis or paired t test, linear
regression, and Pearson correlation test, with a p
value% 0.05 considered significant (*). Error bars
represent median. See also Figures S2 and S3 and
Table S1.challenge), humanmacrophages upregulated EBI2 RNA expres-
sion in only 2 hr with return to basal level after 4 hr (Preuss et al.,
2014), we can hypothesize that EBI2 expression and/or function
may vary in a transient and possibly highly dynamic course in
lymphocytes depending on the disease evolution. Accurate
time points according to the relapses may be necessary to high-
light such changes.
EBI2 is important for the migration of myeloid and lymphoid
cells in steady-state and inflammatory conditions (Chalmin
et al., 2015; Chiang et al., 2013; Gatto et al., 2013; Hannedouche
et al., 2011; Kelly et al., 2011; Liu et al., 2011; Pereira et al., 2009;
Preuss et al., 2014; Rutkowska et al., 2015; Suan et al., 2015; Yi
et al., 2012). We can therefore hypothesize that EBI2 may also
play a role in organ-specific migration of memory cells during220 Cell Reports 18, 213–224, January 3, 2017normal or pathologic conditions or partic-
ipate in CD4+ T cell homing to secondary
lymphoid organs. Regarding the latter hy-
pothesis, given that EBI2 expression in
peripheral blood naive CD4+ T cells is
very low and that, in the memory subsets,
we did not see any difference in expres-
sion between central and effector mem-
ory T cells, it is unlikely that EBI2 might
specifically participate in this process.
However, the observation by Preuss
et al. (2014) that EBI2 RNA transcripts
are maximal in human primary mono-
cytes and upregulated in M0 macro-
phages upon LPS challenge brings argu-ments for a potential role of EBI2 for site-specific migration of
immune cells during inflammatory settings. Future investigations
are required to clarify this point.
We further assessed EBI2 expression in RRMSpatients before
and during NTZ treatment. A significant increase of EBI2 expres-
sion was observed in memory CD4+ T cell subpopulations, but
not in CD8+ T cell or in CD19+ B cell subsets of patients under-
going NTZ treatment, with a parallel gain in the migration rate to-
ward 7a,25-OHC compared to before treatment onset. Those
changes are likely specific to NTZ, because other DMTs do not
elicit such a response and EBI2 expression was not correlated
with disease severity or duration. The effects of NTZ treatment
on EBI2 could be either direct or indirect. We favor the second
postulate, because the sole addition of NTZ on PBMCs was
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Figure 5. NTZ-Treated Patients Depict Decreased CD11a Expression in T Cell Subsets
PBMCs from HDs and NTZ patients were analyzed by flow cytometry.
(A) CD11a expression in NTZ T0 and T9–T12 shown as mean fluorescence intensity in CD4+ and CD8+ T cell naive versus memory subsets and in total B cells
(n = 11).
(B) Percentages of memory CD4+ T cells expressing EBI2 and/or CD11a shown on representative dot plots (left panels) and on a graphic (right panel) (n = 11).
Statistics using paired t test, linear regression, and Pearson correlation test.not sufficient to induce EBI2 at the protein level. This is reminis-
cent of the effect of NTZ on lymphocyte proliferation described
previously, in which the increased number of lymphocytes
observed in the blood of patients under NTZ treatment did not
correlate with an increase in lymphocyte proliferation obtained
from PBMCs when NTZ was added in vitro (Kivisa¨kk et al.,
2009). As another option, EBI2 upregulation in memory CD4+
T cells could be driven in a different compartment than blood
(such as in the bone marrow or in secondary lymphoid organs),
potentially requiring interactions in vivo that are still to be
explored. Besides, the increase in EBI2 expression is mirrored
by a decrease in CD11a (LFA-1) expression. On this point, the
upregulation of one receptor can be potentially related to the
downregulation of another through imbalances in recruitment
of common adaptor molecules. In addition, EBI2 is mainly co-ex-
pressed on memory CD4+ T cells with LFA-1 in untreated RRMS
patients, while under NTZ treatment, a significant subset of CD4+
T cells were EBI2+ but LFA-1. These changes in receptor co-
expression might affect the migration of CD4+ T cells and the
disease evolution in particular under NTZ treatment. Further in-
vestigations are needed to better understand the interplay
among integrins, chemokine receptors, and EBI2 during MS
and in particular under DMTs such as NTZ.
NTZ treatment is associated with an increased risk of progres-
sive multifocal leukoencephalopathy (PML), due to John Cun-
ningham (JC) virus reactivation or infection (McGuigan et al.,
2016). Because T cells are important for brain immune surveil-
lance (Dubois et al., 2015), an increase in EBI2 detection and
function in the context of NTZ administration could be a compen-
satory reaction to favor CD4+ T cell homing to the brain and/orcerebrospinal fluid (CSF). It would be interesting to test whether
a lack of EBI2 upregulation may affect PML development. How-
ever, it is not clear whether this increase in EBI2 expression un-
der NTZ plays a role in the ‘‘rebound’’ effect of disease burden,
which often follows NTZ arrest. Brain inflammatory infiltrates in
patients with rebound effect are mainly constituted of CD8+
T cells with CD4+ T cells concomitantly enriched in CSF, while
during NTZ treatment, CD4+ T cells are dramatically diminished
in CSF, suggesting an important role for the latter cells in this
compartment (Larochelle et al., 2016; St€uve et al., 2006). EBI2
might be involved in the localization of these cells; therefore,
its expression changes under NTZ could have potential effects
on disease activity. Previous works have highlighted significant
participation for EBI2 in B and Tfh cells to regulate B cell matu-
ration and T-dependent antibody response, with simultaneous
modulation of the receptor expression to changes in 7a,25-
OHC production by surrounding cells (Hannedouche et al.,
2011; Li et al., 2016; Suan et al., 2015; Yi et al., 2012). Therefore,
we can hypothesize that there may be EBI2-oxysterol cross-talk
betweenmemory CD4+ T cells and the blood brain barrier (BBB).
This interaction could be affected by NTZ treatment; thus, T cell
migrationmay be affected. It remains to be unraveled whether an
oxysterol gradient can be generated by the BBB, potentially
involving 7a,25-OHC production by the endothelium, pericytes,
or perivascular space macrophages. The 7a,25-OHC synthesiz-
ing enzymes are expressed in blood endothelial cells of lymph
nodes (Yi et al., 2012), in macrophages (Preuss et al., 2014),
and in astrocytes (Rutkowska et al., 2016), reinforcing a potential
role for the BBB in oxysterol synthesis. In the setting of the
rebound effect, further investigations are required to betterCell Reports 18, 213–224, January 3, 2017 221
understand the participation of EBI2 in the migration of patho-
genic CD4+ T cells beyond the BBB. Because an inhibitor is
available with NIBR189, which efficiently blocks EBI2 in human
lymphocytes and in NTZ-treated patients, this could open alter-
native therapeutic opportunities.
In conclusion, our work brings additional elements into the
comprehension of the role of EBI2 in human, particularly during
MS and NTZ treatment. Even if many questions are still open,
these results offer a promising field for future studies and innova-
tive perspectives for therapeutic approaches.
EXPERIMENTAL PROCEDURES
Patients
We enrolled 14 healthy donors from Geneva University Hospital Transfusion
Center, two healthy volunteers, 14 patients with RRMS with no DMT undergo-
ing a mild relapse which did not necessitate corticosteroid administration, and
11 patients treated with natalizumab (300mg intraveinously [i.v.] monthly) from
the Lausanne University Hospital (Table 1). The ethical commissions from the
Lausanne University Hospital accepted this study, and all RRMS patients gave
their written informed consent, according to review board guidelines. At the
time of enrollment, the diagnosis of MS was made using the revised McDo-
nald’s criteria 2010 (Polman et al., 2011). Patients were considered relapsing
if a relapse had started within 4 weeks of the blood sample draw. For natalizu-
mab and dimethyl fumarate-treated patients, blood samples were drawn just
before the first administration and then after 9–12 months.
PBMC Extraction, Cryopreservation, and Thawing
All blood sampling used Sarstedt Monovette EDTA K3 tubes. PBMCs were
extracted by gradient centrifugation using either Ficoll-Paque Plus (GE
Healthcare) or Lymphoprep (STEMCELL Technologies). The leukocyte ring
was removed and washed in RPMI (Sigma) completed with penicillin, strepto-
mycin, and glutamine (PSG) (all from Sigma). Viable cells were counted using
trypan blue (Sigma) resuspended in heat-inactivated fetal calf serum (FCS)
90% (Eurobio) with 10% DMSO (Sigma) at 107 cells/mL, and transferred
into cryotubes. Tubes were then frozen and kept in liquid nitrogen. Cells
were thawed and resuspended at 106 cells/mL in the RPMI-PSG-10% FCS
and plated in a 96-well round bottom plate for overnight resting at 37C in a
cell incubator.
Flow Cytometry Analysis
PBMCs (prepared as described earlier) from each patient were separated to
be either directly stained for viability with Live/Dead Fixable Yellow Dead Cell
Stain Kits (Invitrogen) and surface markers or tested for migration assay on
the same day. The cells were first washed in PBS and then stained with
Live/Dead Fixable Dead Cell Stain according to the manufacturer’s instruc-
tions for 30 min in dark on ice, washed again in PBS, and resuspended in
antibodies diluted in PBS-BSA-1%. After 15 min incubation at room temper-
ature (RT) in dark, cells were washed twice in PBS-BSA-1%, and resus-
pended in Phosflow fixation buffer (Becton Dickinson [BD]) for 15 min at RT
in dark. Cells were then washed twice in PBS-BSA-1% and resuspended in
this buffer for flow cytometry analysis. The following antibodies were pur-
chased from eBioscience: CD4 (RPA-T4), CD45RA (HI100), IgG2a isotype
(eBM2a), and CD19 (HIB19). Antibodies were also purchased from Bio-
Legend: CD8 (SK1), CD4 (SK3), CD45RA (HI100), CD56 (HCD56), CD27
(M-T271), and CD19 (HIB19). The following antibodies were purchased
from BD: CD197 (CCR7) (150503), CD11a (HI111), and CD3 (SK7). The fluo-
rochrome-labeled EBI2 antibody (57C9B5C9) was provided by Andreas
Sailer of Novartis. All patient samples were analyzed with a Gallios 3 cytom-
eter (Beckman Coulter).To compensate for laser senescence and improve
comparability of the fluorescences obtained along the study, for each EBI2
phenotypization experiment, voltages were standardized using Rainbow
Calibration particles, eight peaks (BioLegend), with tolerance of a 5% error
margin in each detection canal used. All flow cytometry data were analyzed
using FlowJo software (v.X, Tree Star).222 Cell Reports 18, 213–224, January 3, 2017In Vitro Migration Assay
After thawing, PBMCs were washed in a medium composed of DMEM (Gibco)
complemented with minimal essential medium (MEM) vitamins (1003), MEM
non-essential amino acid solution (1003), sodium pyruvate 1.5 mM, folic
acid 14 mM, L-asparagine 0.3 mM, L-arginine 0.7 mM, L-glutamine 2 mM,
penicillin-streptomycin 100 U/mL, BSA 1%, b-mercaptoethanol 14.3 mM (all
from Sigma-Aldrich) and were resuspended in this medium at 1.5 million
cells/mL. The indicated dilutions of DMSO (Sigma), 7a,25-OHC (provided by
Novartis, reconstituted in DMSO at 10 mM), CXCL12 (Peprotech, reconsti-
tuted in PBS and BSA 0.1% at 100 mg/mL), and NIBR189 (reconstituted in
DMSO at 10 mM) were prepared using the same medium. The 240 mL of
7a,25-OHC, CXCL12, or medium only were added to the lower chamber of a
96-well transwell plate (Corning, 3387); 75 mL of cells, with or without
NIBR189, were then transferred into the top chamber of the transwell. The
plate was then incubated for 3 hr at 37C in a cell incubator. The cells that
migrated into the lower chamber were stained for surface markers and quan-
tified by flow cytometry using fluorescent beads (Flow-Count Fluorospheres,
Beckman Coulter) and a Gallios 3 cytometer (Beckman Coulter). A pre-defined
number of beads were added directly to cells for a total initial volume of 200 mL.
The number of beads finally counted by the cytometer was then used to calcu-
late the effective volume analyzed in each tube so that the accurate number of
cells per microliter in each tube could be calculated.Cytotoxicity Assay and Cell Viability
7a,25-OHC and NIBR189 cell toxicity was assessed using the Pierce lactate
dehydrogenase (LDH) cytotoxicity assay kit (Thermo Scientific). Human
PBMCs were thawed and plated in RPMI-PSG-10% FCS for overnight resting.
Then, cells were washed, counted, and resuspended in the medium used for
migration assay (described earlier). After plating at 1.5 million cells/mL in a
96-well plate with 10 mL water, DMSO (amount equivalent to a concentration
of 7a,25-OHC 3,000 nM), 7a,25-OHC 300 nM, 7a,25-OHC 3,000 nM, or
NIBR189 25 nM, they were incubated for 3 hr in a cell incubator at 37C. Lysis
buffer (103) furnished by the manufacturer was used as positive control, water
was used as negative control, and the percentage of LDH release secondary to
cell lysis was measured by spectrophotometry. To test for cell viability in the
presence of NIBR189, PBMCs were thawed, rested, and incubated 3 hr at
37C with NIBR189 at the concentration of 25 nM in the same way as for the
cytotoxicity assay. Then, cells were stained with Live/Dead Fixable Dead
Cell Stain as described in the Flow Cytometry Analysis section and analyzed
with a Gallios 3 cytometer (Beckman Coulter).Statistical Analysis
Statistical analysis was performed with GraphPad Prism software v.7. The dif-
ferences in the immune populations were analyzed with two-way ANOVA
associated to Tukey’s multiple comparison post hoc analysis or unpaired t
test when appropriate, and paired t test was used to analyze the difference be-
tween time points. A p value% 0.05 was considered significant. For correlation
analysis, linear regression test and Pearson correlation test were used.SUPPLEMENTAL INFORMATION
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